- A prominent biotechnology company in the United States announced some good news on July 14
- It revealed that a vaccine candidate for COVID-19 is set to enter the final stage of human trials
- Around 30 thousand people will be recruited as participants to the much-awaited process
- It is said that the vaccine candidate being developed by Moderna is leading the global race for the possible cure against the virus
A vaccine candidate for the novel coronavirus disease is set to enter the third and final stage of human trials later this month.
KAMI learned that Moderna, a prominent biotechnology firm in the United States, announced the said development on Tuesday, July 14.
The Phase 3 trial of the said possible treatment against the virus will begin on July 27.
As reported by Agence France-Presse, there will be around 30 thousand people who will participate in the final stage of human trials.
Half of the number of participants will only receive 100 microgram dose levels, while the other half will be given a placebo.
It was revealed, however, that the monitoring will last up to 2 years since researchers have to study the effects of the vaccine candidate to the human body.
It is expected to determine whether the treatment can protect people from getting infected and if it prevents symptoms from developing.
Meanwhile, the New England Journal of Medicine reported that the said vaccine candidate from Moderna made 45 participants develop antibodies against the virus.
The novel coronavirus disease pandemic is one of the most fatal and difficult health crises that the world has ever faced.
Recently, the pharmaceutical firm called Regeneron also announced that a possible drug against the virus has entered the final stage of clinical trials.
In the midst of the global race for the first COVID-19 vaccine, the World Health Organization (WHO) decided to put an end to the trials of two other candidates.
Please like and share our Facebook posts to support KAMI team! Don’t hesitate to comment and share your opinion about our stories either. We love reading about your thoughts!